TY - JOUR
T1 - A new technology for stabilization of biomolecules in tissues for combined histological and molecular analyses
AU - Viertler, Christian
AU - Groelz, Daniel
AU - Gündisch, Sibylle
AU - Kashofer, Karl
AU - Reischauer, Bilge
AU - Riegman, Peter H.J.
AU - Winther, Rosa
AU - Wyrich, Ralf
AU - Becker, Karl Friedrich
AU - Oelmller, Uwe
AU - Zatloukal, Kurt
N1 - Funding Information:
Supported by the European Union Seventh Framework Programme, project SPIDIA (grant no. 222916 to C.V., D.G., S.G., B.R., P.H.J.R., R.W., R.W., K.-F.B., U.O., and K.Z.), and by the Austrian Genome Programme GEN-AU (grant no. 820964 to K.Z.).
Funding Information:
Disclosures: D.G., R.W., and U.O. are employed by Qiagen and have stock options or bond holdings in the company's pension plan. R.W. is employed by Dako, Denmark. The data presented in this manuscript refer to the PAXgene Tissue System, which has been developed in a joint effort by Qiagen and PreAnalytiX and has been evaluated within the SPIDIA consortium, which is publicly funded by the European Commission. The SPIDIA consortium is led by U.O., who is R&D Vice President at Qiagen.
PY - 2012/9
Y1 - 2012/9
N2 - For accurate diagnosis, prediction of outcome, and selection of appropriate therapies, the molecular characterization of human diseases requires analysis of a broad spectrum of altered biomolecules, in addition to morphological features, in affected tissues such as tumors. In a high-throughput screening approach, we have developed the PAXgene Tissue System as a novel tissue stabilization technology. Comprehensive characterization of this technology in stabilized and paraffin-embedded human tissues and comparison with snap-frozen tissues revealed excellent preservation of morphology and antigenicity, as well as outstanding integrity of nucleic acids (genomic DNA, miRNA, and mRNA) and phosphoproteins. Importantly, PAXgene-fixed, paraffin-embedded tissues provided RNA quantity and quality not only significantly better than that obtained with neutral buffered formalin, but also similar to that from snap-frozen tissue, which currently represents the gold standard for molecular analyses. The PAXgene tissue stabilization system thus opens new opportunities in a variety of molecular diagnostic and research applications in which the collection of snap-frozen tissue is not feasible for medical, logistic, or ethical reasons. Furthermore, this technology allows performing histopathological analyses together with molecular studies in a single sample, which markedly facilitates direct correlation of morphological disease phenotypes with alterations of nucleic acids and other biomolecules.
AB - For accurate diagnosis, prediction of outcome, and selection of appropriate therapies, the molecular characterization of human diseases requires analysis of a broad spectrum of altered biomolecules, in addition to morphological features, in affected tissues such as tumors. In a high-throughput screening approach, we have developed the PAXgene Tissue System as a novel tissue stabilization technology. Comprehensive characterization of this technology in stabilized and paraffin-embedded human tissues and comparison with snap-frozen tissues revealed excellent preservation of morphology and antigenicity, as well as outstanding integrity of nucleic acids (genomic DNA, miRNA, and mRNA) and phosphoproteins. Importantly, PAXgene-fixed, paraffin-embedded tissues provided RNA quantity and quality not only significantly better than that obtained with neutral buffered formalin, but also similar to that from snap-frozen tissue, which currently represents the gold standard for molecular analyses. The PAXgene tissue stabilization system thus opens new opportunities in a variety of molecular diagnostic and research applications in which the collection of snap-frozen tissue is not feasible for medical, logistic, or ethical reasons. Furthermore, this technology allows performing histopathological analyses together with molecular studies in a single sample, which markedly facilitates direct correlation of morphological disease phenotypes with alterations of nucleic acids and other biomolecules.
UR - http://www.scopus.com/inward/record.url?scp=84865097319&partnerID=8YFLogxK
U2 - 10.1016/j.jmoldx.2012.05.002
DO - 10.1016/j.jmoldx.2012.05.002
M3 - Article
C2 - 22749745
AN - SCOPUS:84865097319
SN - 1525-1578
VL - 14
SP - 458
EP - 466
JO - Journal of Molecular Diagnostics
JF - Journal of Molecular Diagnostics
IS - 5
ER -